From Wikipedia, the free encyclopedia
Jump to: navigation, search

BMS-663068 is a novel HIV entry inhibitor and a prodrug of BMS-626529, and is under development by Bristol-Myers Squibb for use in the treatment of HIV infection. By blocking the gp120 receptor of the virus, it prevents initial viral attachment to the host CD4+ T cell and entry into the host immune cell; its method of action is a first for HIV drugs. [1] Because it targets a different step of the viral lifecycle, it offers promise for individuals with virus that has become highly resistant to other HIV drugs. [2] Since gp120 is a highly conserved area of the virus, the drug is unlikely to promote resistance to itself via generation of CD4-independent virus. [3]